The American Association of Family Physicians’ 2022 clinical practice guideline on blood pressure (BP) targets in adults with hypertension recommends a ceiling target to reduce the risk of all cause and cardiovascular mortality, and a separate target to reduce likelihood of myocardial infarction in those with that risk.
Distinctions between the 2 recommended targets and the supporting evidence, as well as the guidance from the AAFP on making treatment decisions and on attaining and maintaining target blood pressure levels are the topics of the following 10 questions.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.